Navigation Links
Schering-Plough Reports Financial Results for Third Quarter of 2007
Date:10/22/2007

ting most of its financing plan by securing nearly $9 billion in financing through a mix of equity and debt of varying maturities (3-30 years). The company has completed a customary consultative process with the OBS Works Council in the Netherlands in a positive manner, which will facilitate the transaction with Akzo Nobel.

"The acquisition of Organon BioSciences will create a world-class human health business balanced by the diversification of a world-class animal health business, with its cash flow and strong operating margins," said Hassan. "We will be focused relentlessly on doing the right things to realize the enormous long-term promise of this combination. This means focusing on top-line growth, advancing key R&D projects, continuing to achieve productivity gains across the company and forging a unified, high-performance culture."

In connection with the European Commission clearance, Schering-Plough has agreed to divest certain animal health products in Europe. The divestitures are not expected to be material to the company's financial results. Schering- Plough still needs to secure certain other regulatory approvals, including clearance from the U.S. Federal Trade Commission (FTC), and continues to expect the transaction to be completed by year-end 2007.

Third Quarter 2007 Results

For the 2007 third quarter, Schering-Plough reported net income available to common shareholders of $713 million or 45 cents per common share on a GAAP basis. Excluding acquisition-related items and an upfront R&D payment, earnings per share for the 2007 third quarter would have been 28 cents. The GAAP results include a favorable impact of 17 cents per share comprised of a net benefit of $294 million for acquisition-related items (primarily due to a mark-to-market gain on a currency option) and a charge of $20 million for an upfront licensing payment.

For the 2006 third quarter, the company reported net income available to common shareholders of $287 m
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Asmanex Twisthaler launched by Schering-Plough for treatment of asthma
2. Autopsy reports could be valuable and informative
3. China reports declining number of SARS Cases
4. Russia Reports First SARS Case
5. Research reports that c-section deliveries are rising
6. Jharkhand reports 13,000 Malaria cases
7. Uganda Reports Failure To Contain Sleeping Sickness
8. WHO reports 36 million deaths world wide due to chronic diseases
9. Reports of Hantavirus infection in India raise concerns
10. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
11. China Reports Yet Another Bird Flu Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... ... opinion piece published July 28 by the Washington Post, the conventional wisdom that ... not be accurate. While this system may work for some people, the author notes that ... on the individual and at what point that person is in their weight loss journey. ...
(Date:8/3/2015)... ... , ... Bayer has agreed to pay $56.9 million to set up a ... to have suffered an arterial blood clot including stroke and heart attack. The litigation ... has been ongoing for well-over five years. In 2009, lawsuits filed against Bayer involving ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... contract research organisations (CROs) for a slew of benefits, allowing them to gain ... operations, boost quality with cost-effective utilisation of resources, get access to innovation and ...
(Date:8/3/2015)... ... 2015 , ... A recent survey by the National ... believe people can positively affect their diabetes, few look beyond diet changes to ... changes was important. Far fewer participants mentioned the need for exercise (30%), maintaining ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... for Provider Profiling, Predictive Modeling, Resource Management and ... DST Health Solutions today announced the ... DSTHS RiskAnalyzer(TM). RiskAnalyzer uses claims experience to determine ... under the Centers for Medicare and Medicaid Services ...
... QHR hospital clients received unexpected checks totaling nearly ... ranging from $65,000 to more than $750,000 - ... a unique and innovative partnership between the hospital ... Under the QHR/Gallagher Retro Insurance Program, hospital groups ...
... cadherin superfamily has a correlate relationship with the ... suggested that, unlike E-cadherin, N-cadherin may promote motility ... pathological significance of E-cadherin and N-cadherin expressions in ... led by Prof. Qing-Xia Fan from China detected ...
... 100,000 Swedes are under treatment with the blood-thinning drug ... makes the initiation of treatment a risky balancing act ... Uppsala University have developed a model for calculating the ... in the scientific publication New England Journal of ...
... PURCHASE, N.Y., Feb. 19 The PepsiCo Foundation ... Save the Children to help ensure the survival ... and Bangladesh, which together are home to 40 ... )With support from the PepsiCo Foundation, Save ...
... 19 Cardium Therapeutics (NYSE Alternext US: CXM) ... on January 23, 2009 has been accepted by ... Stock Exchange). (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO )As ... from the staff of its current listing exchange ...
Cached Medicine News:Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 2Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 3Health News:QHR, Gallagher Partnership Yields More Thank $4 Million for QHR Hospital Clients 2Health News:Knowledge of genetics improves uncertain medication 2Health News:PepsiCo Foundation Announces Grant to Save the Children to Address Malnutrition in Developing Nations 2Health News:PepsiCo Foundation Announces Grant to Save the Children to Address Malnutrition in Developing Nations 3Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 2Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 3Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 4Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 5
(Date:8/3/2015)... 3, 2015 /OFF HOLD ... LLC, PIV757417 The following release: "Biotech Advancements Coupled ... Products & Treatments for Critical-Care Patients With Severe ... 3 Aug 2015 12:30 GMT Cooperative ... surgical research and top-tier universities for identifying biotech ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... , August 3, 2015 BiondVax Pharmaceuticals ... statistical analysis of results from a study which demonstrates that ... II trial which took place in 2012, provided participants with ... the time of the study- in particular the current newly ... the United States in 2015. ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: